Therapeutic benefits of methylene blue on cognitive impairment during chronic cerebral hypoperfusion

Journal of Alzheimer's Disease

Volumn 42, Issue , 2014, Pages S525-S535

  Auchter, Allison ^a   Williams, Justin ^a   Barksdale, Bryan ^a   Monfils, Marie H ^a   Gonzalez Lima, Francisco ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Carotid occlusion; cerebral hypoperfusion; cognitive impairment; memory enhancement; methylene blue

Indexed keywords

METHYLENE BLUE; ENZYME INHIBITOR;

ADULT; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAROTID ARTERY OBSTRUCTION; CEREBROVASCULAR ACCIDENT; CHRONIC BRAIN DISEASE; CHRONIC CEREBRAL HYPOPERFUSION; COGNITIVE DEFECT; CONTROLLED STUDY; DISCRIMINATION LEARNING; DISEASE ASSOCIATION; DRUG EFFICACY; EXPERIMENTAL AMNESIA; EXPERIMENTAL BEHAVIORAL TEST; LEARNING DISORDER; LOCOMOTION; LOW DRUG DOSE; MALE; MEMORY CONSOLIDATION; MOTOR ACTIVITY; MOTOR PERFORMANCE; NONHUMAN; ODOR RECOGNITION TEST; OPEN FIELD TEST; RAT; SWIMMING; VISUAL MEMORY; VISUAL WATER MAZE TEST; ANALYSIS OF VARIANCE; ANIMAL; COMPLICATION; CORONARY ARTERY OCCLUSION; DISEASE MODEL; DRUG EFFECTS; EXPLORATORY BEHAVIOR; LEARNING; LONG EVANS RAT; MILD COGNITIVE IMPAIRMENT; ODOR; PHYSIOLOGY; RECOGNITION;

ANALYSIS OF VARIANCE; ANIMALS; ASSOCIATION LEARNING; CORONARY OCCLUSION; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; EXPLORATORY BEHAVIOR; LOCOMOTION; MALE; METHYLENE BLUE; MILD COGNITIVE IMPAIRMENT; MOTOR ACTIVITY; ODORS; RATS; RATS, LONG-EVANS; RECOGNITION (PSYCHOLOGY);

EID: 84908221239     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-141527     Document Type: Article

References (54)

1. d e laTorre JC (2010)Vascular risk factor detection and control may prevent Alzheimer's disease. Ageing Res Rev 9, 218-225.
2. de la Torre JC (2012) Cerebral hemodynamics and vascular risk factors: Setting the stage for Alzheimer's disease. J Alzheimers Dis 32, 553-567.
3. de La Torre JC (2012) Cardiovascular risk factors promote brain hypoperfusion leading to cognitive decline and dementia. Cardiovasc Psychiatry Neurol 2012, 367516.
4. Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, Atwood CS, Johnson AB, Kress Y, Vinters HV, Tabaton M, Shimohama S, Cash AD, Siedlak SL, Ha rris PLR, Jones PK, Petersen RB, Perry G, SmithMA(2001) Mitochondrial abnormalities in Alzheimer's disease. J Neurosci 21, 3017-3023.
5. Velliquette RA, O'Connor T, Vassar R (2005) Energy inhibition elevates beta-secretase levels and activity and is potentially amyloidogenic in APP transgenic mice: Possible early events in Alzheimer's disease pathogenesis. J Neurosci 25, 10874-10883.
6. Hauptmann S, Scherping I, Dr öse S, Brandt U, Schulz KL, Jendrach M, Leuner K, Eckert A, Müller WE (2009) Mitochondrial dysfunction: An early event in Alzheimer pathology accumulates with age in ADtransgenic mice. Neurobiol Aging 30, 1574-1586.
7. Cada A, de la Torre JC, Gonzalez-Lima F (2000) Chronic cerebrovascular ischemia in aged rats: Effects on brain metabolic capacity and behavior. Neurobiol Aging 21, 225-233.
8. Obrenovich ME, Smith MA, Siedlak SL, Chen SG, Torre JC, Perry G, Aliev G (2006) Overexpression of GRK2 in Alzheimer disease and in a chronic hypoperfus ion rat model is an early marker of brain mitochondrial lesions. Neurotox Res 10, 43-56.
9. Bruchey AK, Gonzalez-Lima F (2008) Behavioral, physiological and biochemical hormetic responses to the autoxidizable dye methylene blue. Am J Pharmacol Toxicol 3, 72-79.
10. Wainwright M, Crossley K (2002) Methylene blue-A therapeutic dye for all seasons? J Chemother 14, 431-443.
11. Peter C, Hongwan D, Küpfer A, Lauterburg BH (2000) Pharmacokinetics and organ distribution of intravenous and oral methylene blue. Eur J Clin Pharmacol 56, 247-250.
12. Visarius TM, Stucki JW, Lauterburg BH (1997) Stimulation of respiration by methylene blue in rat liver mitochondria. FEBS Lett 412, 157-160.
13. Callaway NL, Riha PD, Bruchey AK, Munshi Z, Gonzalez-Lima F (2004) Methylene blue improves brain oxidative metabolism and memory retention in rats. Pharmacol Biochem Behav 77, 175-181.
14. Riha PD, Bruchey AK, Echevarria DJ, Gonzalez-Lima F ( 2005) Memory facilitation by methylene blue: Dosedependent effect on behavior and brain oxygen consumption. Eur J Pharmacol 511, 151-158.
15. Huang S, Du F, Shih YYI, Shen Q, Gonzalez-Lima F, Duong TQ (2013) Methylene blue potentiates stimulus-evoked fMRI responses and cerebral oxygen consumption during normoxia and hypoxia. Neuroimage 72, 237-242.
16. Lee RB, Urban JPG (2002) Functional replacement of oxygen by other oxidants in articular cartilage. Arthritis Rheum 46, 3190-3200.
17. Salaris SC, Babbs CF, Voorhees WD (1991) Methylene blue as an inhibitor of superoxide generation by xanthine oxidase. Biochem Pharmacol 42, 499-506.
18. Zhang XC, Rojas J, Gonzalez-Lima F (2006) Methylene blue prevents neurodegeneration caused by rotenone in the retina. Neurotox Res 9, 47-57.
19. Rojas J, Gonzalez-lima F (2010) Mitochondrial optic neuropathy: In vivo model of neurodegeneration and neuroprotective strategies. Eye Brain 2, 21-37.
20. Rojas JC, Bruchey AK, Gonzalez-Lima F (2012) Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue. Prog Neurobiol 96, 32-45.
21. Gonzalez-Lima F, Barksdale BR, Rojas JC (2014) Mitochondrial respiration as a target for neuroprotection and cognitive enhancement. Biochem Pharmacol 88, 584-593.
22. Callaway NL, Riha PD, WrubelKM,McCollum D, Gonzalez-Lima F (2002) Methylene blue restores spatial memory retention impaired by an inhibitor of cytochrome oxidase in rats. Neurosci Lett 332, 83-86.
23. Riha PD, Rojas JC, Gonzalez-Lima F (2011) Beneficial network effects of methylene blue in an amnestic model. Neuroimage 54, 2623-2634.
24. Gonzalez-Lima F, Bruchey AK (2004) Extinction memory improvement by the metabolic enhancer methylene blue. Learn Mem 11, 633-640.
25. Wrubel KM, Barrett D, Shumake J, Johnson SE, Gonzalez-Lima F (2007) Methylene blue facilitates the extinction of fear in an animal model of susceptibili ty to learned helplessness. Neurobiol Learn Mem 87, 209-217.
26. Wrubel KM, Riha PD, Maldonado MA, McCollum D, Gonzalez-Lima F (2007) The brain metabolic enhancer methylene blue improves dis crimination learning in rats. Pharmacol Biochem Behav 86, 712-717.
27. Paban V, Manrique C, Filali M, Maunoir-Regimbal S, Fauvelle F, Alescio-Lautier B (2014) Therapeutic and preventive effe cts of methylene blue on Alzheimer's disease pathology in a transgenic mouse model. Neuropharmacology 76, 68-79.
28. O'Leary JC, Li Q, Marinec P, Blair LJ, Congdon EE, Johnson AG, Jinwal UK, Koren J, Jones JR, Kraft C, Peters M, Abisambra JF, Duff KE, Weeber EJ, Gestwicki JE, Dickey CA (2010) Phenothiazine-mediated rescue of cognition in tau transgenic mice requires neuroprotection and reduced soluble tau burden. Mol Neurodegener 5, 45.
29. Medina DX, Caccamo A, Oddo S (2011) Methylene blue reduces a-levels and rescues early cognitive deficit by increasing proteasome activity. Brain Pathol 21, 140-149.
30. Deiana S, Harrington CR, Wischik CM, Riedel G (2009) Methylthioninium chloride reverses cognitive deficits induced by scopolamine: Comparison with rivastigmine. Psychopharmacology (B erl) 202, 53-65.
31. Telch MJ,Bruchey AK,Rosenfield D,Cobb A,Smits J,Pahl S,Gonzalez-Lima F 2014 Post-session administration of USP methylene blue facilitates the retention of pa thological fear extinction and contextual memory in phobic adults Am J Psychiatry, 10.1176/appi.ajp.2014.13101407
32. Shumake J, Furgeson-Moreira S, Monfils MH (2014) Predictability and heritability of individual differences in fear learning. Anim Cogn. doi: 10.1007/s10071-014-0752-1
33. de la Torre JC, Fortin T (1991) Partial or global rat brain ischemia: The SCOT model. Brain Res Bull 26, 365-372.
34. de la Torre JC, Fortin T (1994) A chronic physiological rat model of dementia. Behav Brain Res 63, 35-40.
35. Martinez JL, Jensen RA, Vasquez BJ, McGuinness T, McGaugh JL (2013) Methylene blue alters retention of inhibitory avoidance responses. Physiol Psychol 6, 387-390.
36. Prusky GT,West PW, Douglas RM (2000) Behavioral assessment of visual acuity in mice and rats. Vision Res 40, 2201-2209.
37. Driscoll I, Sutherland RJ, Prusky GT, Rudy JW (2004) Damage to the hippocampal formation does not disrupt representational flexibility as measured by a novelty transfer test. Behav Neurosci 118, 1427-1432.
38. Driscoll I, Howard SR, Prusk y GT, Rudy JW, Sutherland RJ (2005) Seahorse wins all races: Hippocampus participates in both linear and non-linear visual discrimination learning. Behav Brain Res 164, 29-35.
39. Alvarado MC, R udy JW (1995) Rats with damage to the hippocampal-formation are impaired on the transversepatterning problem but not on elemental discriminations. Behav Neurosci 109, 204-211.
40. Spinetta MJ,Woodlee MT, Feinberg LM, Stroud C, Schallert K, Cormack LK, Schallert T (2008) Alcohol-induced retrograde memory impairment in rats: Prevention by caffeine. Psychopharmacology (Berl) 201, 361-371.
41. Tillerson JL, Caudle WM, Parent JM, Gong C, Schallert T, Miller GW (2006) Olfactory discrimination deficits in mice lacking the dopamine transporter or the D2 dopamine receptor. Behav Brain Res 172, 97-105.
42. Crews D, Gore AC, Hsu TS, Dangleben NL, Spinetta M, Schallert T, Anway MD, Skinner MK (2007) Transgenerational epigenetic imprints on mate preference. Proc Natl Acad Sci U S A 104, 5942-5946.
43. Ennaceur A, Neave N, Aggleton JP (1997) Spontaneous object recognition and object location memory in rats: The effects of lesions in the cingulate cortices, the medial prefrontal cortex, the cing ulum bundle and the fornix. Exp Brain Res 113, 509-519.
44. de la Torre JC, Fortin T, Park GA, Pappas BA, Richard MT (1993) Brain blood flow restoration " rescues" chronically damaged rat CA1 neurons. Brain Res 623, 6-15.
45. Paxinos G, Watson C (2007) The Rat Brain in Stereotaxic Coordinates, Sixth Edition. Elsevier Academic Press 170, 547-612.
46. de la Torre JC, Cada A, Nelson N, Davis G, Sutherland RJ, Gonzalez-Lima F (1997) Reduced cytochrome oxidase and memory dysfunction after chronic brain ischemia in aged rats. Neurosci Lett 223, 165-168.
47. Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP, Selby JV (2009) Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA 301, 1565-1572.
48. Clarke DD, Sokoloff L (1999) Circulation and energy metabolism of the brain. In Basic Neurochemistry: Molecular, Cellular and Medical aspects, Siegel GJ, Agranoff BW, Albers RW, Fisher SK, Uhler MD. Lippincott-Ra ven, Philadelphia, pp. 637-669.
49. Mosconi L, Tsui WH, Herholz K, Pupi A, Drzezga A, Lucignani G, Reiman EM, Holthoff V, Kalbe E, Sorbi S, Diehl-Schmid J, Perneczky R, Clerici F, Caselli R, Beuthien-Baumann B, Kurz A, Minoshima S, de Leon MJ (2008) Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J Nucl Med 49, 39 0-398.
50. Valla J, Berndt JD, Gonzalez-Lima F (2001) Energy hypometabolism in posterior cingulate cortex of Alzheimer's patients: Superficial laminar cytochrome oxidase associated with disease duration. J Neuro sci 21, 4923-4930.
51. Valla J, Schneider LE, Small AM, Gonzalez-Lima F (2007) Quantitative cytochrome oxidase histochemistry: Applications in human Alzheimer's disease and animal models. J Hist otechnol 30, 235-247.
52. Valla J,Yaari R,Wolf AB,Kusne Y,Beach TG,Roher AE,Corneveaux JJ,Huentelman MJ,Caselli RJ,Reiman EM 2010 Reduced posterior cingulate mitochondr ial activity in expired young adult carriers of the APOE-4 Allele, the major late-onset Alzheimer's susceptibility gene J Alzheimers Dis 22, 307-313.
53. Morris JC, Storandt M, Miller JP, McKeel DW, Price JL, Rubin EH, Berg L (2001) Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol 58, 397-405.
54. Watts LT, Long JA, Chemello J, Van Koughnet S, F ernandez A, Huang S, Shen Q, Duong TQ (2014) Methylene blue is neuroprotective against mild traumatic brain injury. J Neurotrauma 9, 1-9.